This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 1 of 1 for:    C26003
Previous Study | Return to List | Next Study

A Study of MLN0264 in Patients With Pancreatic Cancer

This study has been terminated.
(Business Decision, No Safety or Efficacy Concerns)
Sponsor:
Information provided by (Responsible Party):
Takeda ( Millennium Pharmaceuticals, Inc. )
ClinicalTrials.gov Identifier:
NCT02202785
First received: July 7, 2014
Last updated: April 6, 2017
Last verified: April 2017
  Purpose
The purpose of this study is to assess the efficacy, safety and tolerability of MLN0264 in patients with advanced or metastatic guanylyl cyclase C (GCC)-positive adenocarcinoma of the pancreas.

Condition Intervention Phase
Pancreatic Adenocarcinoma Drug: MLN0264 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Phase 2 Trial of MLN0264 in Previously Treated Patients With Advanced or Metastatic Pancreatic Adenocarcinoma Expressing Guanylyl Cyclase C (GCC)

Further study details as provided by Takeda ( Millennium Pharmaceuticals, Inc. ):

Primary Outcome Measures:
  • Overall Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors (RECIST) [ Time Frame: Day 21, every other cycle, starting with Cycle 2 until disease progression, death or study closure (Up to 16 months) ]
    ORR is defined as the percentage of participants with complete response (CR) or partial response (PR) as assessed by the investigator using Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. CR: Disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR: At least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions.


Secondary Outcome Measures:
  • Number of Participants With Potentially Clinically Significant Laboratory Evaluation Findings [ Time Frame: Day 1 of each 21 day cycle and 30 days after the last dose of study medication (Up to 7.9 months) ]
    Participants with at least one post-baseline potentially clinically significant serum chemistry, hematology, coagulation or urinalysis result. Clinically significant results are those that were assessed by the investigator to be Grade 3 or higher using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE). Grade 3=severe, Grade 4=life threatening or disabling and Grade 5=Death.

  • Number of Participants With Potentially Clinically Significant Vital Signs Findings [ Time Frame: Day 1 of each 21 day cycle and 30 days after the last dose of study medication (Up to 7.9 months) ]
    Participants with at least one potentially clinically significant post-baseline vital sign finding including measurements of diastolic and systolic blood pressure, heart rate, and oral temperature.

  • Progression Free Survival (PFS) [ Time Frame: Day 21 of every other 21-day cycle starting with Cycle 2, 30 days after the last dose of study medication, and then every 12 weeks for up to an additional 6 months (Up to 13.9 months) ]
    PFS is defined as the time in days from the date of first study drug administration to the date of first documentation of disease progression or death. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

  • Duration of Response [ Time Frame: From first documented response until disease progression (Up to 16 months) ]
    Duration of response is defined as the time from the date of first documentation of a Partial Response or better to the date of first documentation of disease progression or relapse based on investigator assessment using RECIST version 1.1 guidelines. Per RECIST version 1.1 for target lesions and assessed by MRI: CR, Disappearance of all target lesions; PR, >=30% decrease in the sum of the longest diameter of target lesions.

  • Disease Control Rate [ Time Frame: Day 21 of every other 21-day cycle starting with Cycle 2, 30 days after the last dose of study medication, and then every 12 weeks for up to an additional 6 months (Up to 13.9 months) ]
    Disease control rate is defined as the percentage of participants with complete response (CR) or partial response (PR) or stable disease (SD) with a minimum of 12 weeks' duration. Investigator response is based on the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. CR: Disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR: At least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum longest diameter (LD) since the treatment started.

  • Overall Survival (OS) [ Time Frame: Until death or 6 months after the last patient completes treatment—whichever occurs first (Up to 16 months) ]
    Overall survival is defined as the time in days from the date of first study drug administration to the date of death.

  • Cmax: Maximum Observed Serum Concentration for MLN0264 [ Time Frame: Cycles 1-3 predose and 10 minutes, 4 hours, and 3, 4, 8 and 15 days postdose. Cycles 4+ predose, 10 minutes, 4 hours, and 4 and 8 days postdose. ]
  • Serum Concentration of Monomethyl Auristatin E (MMAE) [ Time Frame: Cycles 1-3 predose and 10 minutes, 4 hours, and 3, 4, 8 and 15 days postdose. Cycles 4+ predose, 10 minutes, 4 hours, and 4 and 8 days postdose. ]
    Blood samples were collected and sent to a laboratory to be tested for MMAE.

  • Guanylyl Cyclase C (GCC) H-score Assessed by Immunohistochemistry (IHC) [ Time Frame: From pre-screening through end of study (approximately 18 months) ]
    GCC H-score is based on the sum of the 0 to 300 H-score for cytoplasmic staining and the 0 to 300 H-score for apical staining for a total possible H-score 0 to 600. Separate consent is required to obtain archival tumor specimens for GCC expression assessment prior to screening.

  • Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: From the first dose through 30 days after the last dose of study medication (Up to 7.9 months) ]
    An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with this treatment. An SAE is defined as any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly/birth defect or is a medically important event.

  • MLN0264 Serum Concentrations [ Time Frame: Cycles 1-3 predose and 10 minutes, 4 hours, and 3, 4, 8 and 15 days postdose. Cycles 4+ predose, 10 minutes, 4 hours, and 4 and 8 days postdose. ]
    Blood samples were collected and sent to a laboratory to be tested for serum concentrations of MLN0264.

  • Serum Concentration of Total Antibodies (Conjugated and Unconjugated) [ Time Frame: Cycles 1-3 predose and 10 minutes, 4 hours, and 3, 4, 8 and 15 days postdose. Cycles 4+ predose, 10 minutes, 4 hours, and 4 and 8 days postdose. ]
    Blood samples were collected and sent to a laboratory to be tested for conjugated and unconjugated antibodies.

  • Percentage of Participants With Reduction From Baseline in Tumor Size [ Time Frame: Day 21 of each 21-day cycle, 30 days after the last dose of study medication, and then every 12 weeks for up to an additional 6 months (Approximately 13.9 months) ]
    The percentage of participants with the best percentage of tumor reduction from baseline in the sum of the diameter was calculated

  • Number of Participants With Antitherapeutic Antibodies (ATA) [ Time Frame: Pre-dose of each 21 day cycle and 30 days after last dose of study medication (Up to 7.9 months) ]
    Blood samples were collected to assess the immunogenicity of MLN0264 (ATA development) using a laboratory test. Neutralizing ATA assessment was performed for ATA-positive samples only.


Enrollment: 43
Study Start Date: July 2, 2014
Study Completion Date: January 15, 2016
Primary Completion Date: January 15, 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: MLN0264 1.8 mg/kg
MLN0264 1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 of each 21-day cycle, for up to 1 year or until disease progression or unacceptable toxicity occurs (Up to 10 cycles). The dose may be decreased, delayed or discontinued in participants who develop treatment-associated nonhematologic and hematologic toxicity to MLN0264.
Drug: MLN0264
MLN0264 IV infusion

Detailed Description:

The drug being tested in this study is called MLN0264. MLN0264 is being tested to treat tumors in people who have metastatic adenocarcinoma of the pancreas expressing guanylyl cyclase C (GCC). This study will assess tumor size reduction in patients who are administered MLN0264.

The study will enroll 42 to 81 patients. All participants will be administered MLN0264 at 1.8 mg/kg as a single, 30-minute, intravenous (IV) infusion on Day 1 of each 3-week treatment cycle, followed by a rest period of 20 days. Participants will continue to receive MLN0264 for up to 1 year or until disease progression or unacceptable toxicity occurs.

This multi-centre trial will be conducted worldwide. The overall time to participate in this study is approximately 19 months. Participants will make 3 to 6 visits to the clinic per treatment cycle, an end-of-treatment visit will occur 30 days after the last dose of study medication, and follow-up assessments will occur every 12 weeks until death or 6 months after the last patient completes treatment - whichever occurs first.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female participants 18 years of age or older when written informed consent is obtained.
  2. Histologically confirmed metastatic or advanced inoperable adenocarcinoma of the pancreas with immunohistochemistry (IHC) evidence of guanylyl cyclase C (GCC) expression indicated by an H-score of 10 or greater.
  3. Treatment with 1 or more prior chemotherapies for advanced or metastatic adenocarcinoma of the pancreas.
  4. Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 guidelines. All scans and x-rays used to document measurable disease must be done within 28 days before enrollment (ascites and bone lesions are not considered measureable disease).
  5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 14 days before enrollment.
  6. Female participants who:

    • Are postmenopausal for at least 1 year before the screening visit, OR
    • Are surgically sterile, OR
    • If they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent through 30 days after the last dose of study drug, or
    • Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable methods of contraception.)

    Male participants, even if surgically sterilized (ie, status postvasectomy), who:

    • Agree to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug, or
    • Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods for the female partner] and withdrawal are not acceptable methods of contraception.)
  7. Voluntary written consent must be given before performance of any study-related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the participant at any time without prejudice to future medical care.
  8. Adequate organ and hematological function as evidenced by the following laboratory values within 14 days before enrollment:

    • Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L
    • Platelet count ≥ 100 x 10^9/L
    • Hemoglobin ≥ 9 g/dL
    • Activated partial thromboplastin time (aPTT) ≤ 1.5 x the upper limit of the normal range (ULN) per institutional laboratory normal range
    • International normalized ratio (INR) ≤ 1.5 x ULN
    • Serum creatinine ≤ 1.5 x ULN
    • Total bilirubin ≤ 1.5 x ULN
    • Albumin ≥ 3g/dL
    • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN
    • Serum lipase ≤ 3 x ULN and serum amylase within the normal range
  9. Resolution of all toxic effects of prior treatments except alopecia to Grade 0 or 1 by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03.
  10. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures.

Exclusion Criteria:

  1. Radiotherapy within 4 weeks before enrollment.
  2. Concurrent treatment or treatment within 4 weeks of study entry with any other investigational agent or chemotherapy.
  3. Female participants who are lactating and breastfeeding or have a positive pregnancy test during the Screening period.
  4. Uncontrolled, clinically significant, symptomatic cardiovascular disease within 6 months before enrollment, including myocardial infarction, unstable angina, Grade 2 or greater peripheral vascular disease, cerebrovascular accident, transient ischemic attack, congestive heart failure, or arrhythmias not controlled by outpatient medication.
  5. Treatment with any medication that has a clinically relevant potential risk of prolonging the QT interval or inducing torsades de pointes that cannot be discontinued or switched to a different medication before starting study drug.
  6. Participants with electrocardiogram (ECG) abnormalities considered by the investigator to be clinically significant, or repeated baseline prolongation of the rate-corrected QT interval (QTc).
  7. Ongoing or clinically significant active infection as judged by the investigator.
  8. Signs of peripheral neuropathy (PN) ≥ NCI CTCAE Grade 2.
  9. Concomitant chemotherapy, hormonal therapy, immunotherapy, or any other form of cancer treatment.
  10. Use of strong cytochrome P450 (CYP) 3A4 inhibitors within 2 weeks before the first dose of study drug.
  11. Any preexisting medical condition of sufficient severity to prevent full compliance with the study.
  12. History of or current neoplasm other than gastric adenocarcinoma, except for curatively treated nonmelanoma skin cancer or in situ carcinoma of the cervix uteri.
  13. Known diagnosis of human immunodeficiency virus (HIV) infection (testing is not mandatory).
  14. Symptomatic brain metastases.
  15. Ongoing anticoagulant therapy (eg, aspirin, coumadin, heparin).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02202785

Locations
United States, Colorado
Aurora, Colorado, United States
United States, Florida
St. Petersburg, Florida, United States
Tampa, Florida, United States
United States, Massachusetts
Boston, Massachusetts, United States
United States, Ohio
Cincinnati, Ohio, United States
United States, Tennessee
Nashville, Tennessee, United States
United States, Texas
San Antonio, Texas, United States
Belgium
Brugge, Belgium
Leuven, Belgium
Spain
Barcelona, Spain
Madrid, Spain
Malaga, Spain
Sevilla, Spain
United Kingdom
London, Greater London, United Kingdom
Manchester, Greater Manchester, United Kingdom
Sutton, Surrey, United Kingdom
Sponsors and Collaborators
Millennium Pharmaceuticals, Inc.
Investigators
Study Director: Medical Director Clinical Science Millennium Pharmaceuticals, Inc.
  More Information

Responsible Party: Millennium Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT02202785     History of Changes
Other Study ID Numbers: C26003
2014-000805-11 ( EudraCT Number )
U1111-1155-8964 ( Other Identifier: WHO )
REec-2014-1177 ( Other Identifier: REec )
Study First Received: July 7, 2014
Results First Received: January 13, 2017
Last Updated: April 6, 2017

Keywords provided by Takeda ( Millennium Pharmaceuticals, Inc. ):
Drug therapy

Additional relevant MeSH terms:
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms

ClinicalTrials.gov processed this record on June 27, 2017